Member Name: {{MEMFIRST}} {{MEMLAST}} DOB: {{MEMBERDOB}} PA Number: {{PANUMBER}}



Strensiq

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155. If you have questions regarding the prior authorization, please contact CVS Caremark at 1-866-814-5506. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Pat Phy	tient's Name: {{MEMFIRST}} {{MEMLAST}} Date: {{TODAY}} tient's ID: {{MEMBERID}} Patient's Date of Birth: {{MEMBERDOB}} sysician's Name: {{PHYFIRST}} {{PHYLAST}} tricking the state of Birth: {{MEMBERDOB}} sysician's Name: {{PHYFIRST}} {{PHYLAST}} tricking the state of Birth: {{MEMBERDOB}} sysician's Name: {{PHYFIRST}} {{PHYLAST}} tricking the state of Birth: {{PHYSICIANFAX}}		
	quest Initiated For: {{DRUGNAME}}		
1.	What is the patient's diagnosis? ☐ Hypophosphatasia ☐ Other		
2.	What is the ICD-10 code?		
3.	What is the patient's: A) Heightin		
	B) Weightkg		
4.	What is the weekly prescribed dosage?mg/kg		
5.	When was the onset of the diagnosis? ☐ Perinatal/infantile-onset ☐ Adult-onset ☐ Other		
6.	Is the patient currently receiving treatment with the requested medication? Yes No If No, skip to #12		
7.	Is the patient currently receiving the requested medication through samples or a manufacturer's patient assistance program? <i>If Yes, or Unknown, skip to #12.</i> \square Yes \square No \square Unknown		
8.	Is the patient experiencing a benefit from therapy as demonstrated by an improvement in skeletal manifestations from baseline as assessed by the Radiographic Global Impressions of Change (RGI-C) scale? **ACTION REQUIRED: If Yes, please submit medical record of Radiographic Global Impression of Change (RGI-C) scale. If Yes, no further questions Yes No		
9.	Is the patient less than 18 years of age and is experiencing a benefit from therapy as demonstrated by an improvement in height and weight compared to baseline, as measured by z-scores? ACTION REQUIRED: If Yes please submit medical record of Radiographic Global Impression of Change (RGI-C) scale. If Yes, no further questions Yes No		
10.	Is the patient experiencing a benefit from therapy as demonstrated by an improvement in step length by at least 1 point in either foot compared to baseline based on the Modified Performance Oriented Mobility Assessment-Gait (MPOMA-G) scale? ACTION REQUIRED: If Yes, please submit medical record of Modified Performance Oriented Mobility Assessment -Gait score. If Yes, no further questions \square Yes \square No		

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Strensiq SGM - 6/2021.

Me	mber Name: {{MEMFIRST}} {{MEMLAST}} DOB: {{MEMBERDOB}} PA Number: {{PANUMBER}}	
11.	Has the patient experienced an improvement in the 6 Minute Walk Test compared to baseline? **ACTION REQUIRED: If Yes, please submit medical record of distance walked in the 6 Minute Walk Test. □ Yes □ No No further questions	
12.	If patient is 18 years of age or older, did the patient demonstrate clinical signs and symptoms of hypophosphatasia (e.g., skeletal abnormalities, respiratory problems, hypercalcemia, seizures) before the age of 18? ACTION REQUIRED: If Yes, please submit medical record documentation showing presence of condition before the age of 18. Yes No	
13.	Does the patient currently demonstrate clinical signs and/or symptoms of hypophosphatasia (e.g., skeletal abnormalities, respiratory problems, hypercalcemia, seizures)?	
14.	Did the patient test positive for a known pathological mutation in the ALPL gene as determined by molecular genetic testing? <i>ACTION REQUIRED: If Yes, please submit genetic test results and no further questions.</i> Yes No	
15.	Do findings on radiographic imaging at the time of diagnosis demonstrate skeletal abnormalities and support the diagnosis of hypophosphatasia (e.g., infantile rickets, alveolar bone loss, osteoporosis, low bone mineral content for age [as detected by DEXA])? <i>ACTION REQUIRED: If Yes, please submit radiographic imaging results.</i> □ Yes □ No □ Not performed	
16.	 b. How does the patient's pretreatment serum alkaline phosphatase (ALP) level compare to the laboratory's reference normal range based on age and gender? ACTION REQUIRED: Please submit laboratory test results. □ Higher than the laboratory's normal range □ Lower than the laboratory's normal range □ Within the laboratory's normal range 	
17.	Does the patient have an elevated pretreatment level of a tissue-nonspecific alkaline phosphatase (TNSALP) substrate level (i.e., serum pyridoxal 5'-phosphate [PLP] level, serum or urine phosphoethanolamine [PEA] level, urinary inorganic pyrophosphate [PPi level])? <i>ACTION REQUIRED: If Yes, please submit laboratory test results.</i> \square Yes \square No	
Ap	A. Examples of Signs and Symptoms of HPP A. Perinatal/infantile-onset HPP: • Generalized hypomineralization with rachitic features, chest deformities and rib fractures • Skeletal abnormalities (e.g., short limbs, abnormally shaped chest, soft skull bone) • Respiratory problems (e.g., pneumonia) • Hypercalcemia • Failure to thrive • Severe muscular hypotonia and weakness • Nephrocalcinosis secondary to hypercalciuria • Swallowing problems • Seizures	
	 B. Juvenile-onset HPP: List continues on next page. Premature loss of deciduous teeth Failure to thrive with anorexia, nausea, and gastrointestinal problems Short stature with bowed legs or knock knees Skeletal deformities (e.g., enlarged wrist and ankle joints, abnormal skull shape) Bone and joint pain Rickets Fractures Delayed walking Waddling gait 	

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Strensiq SGM - 6/2021.

CVS Caremark Prior Authorization • 1300 E. Campbell Road • Richardson, TX 75081

Member Name: {{MEMFIRST}} {{MEMLAST}} **DOB:** {{MEMBERDOB}} **PA Number:** {{PANUMBER}}

Appendix B. Examples of Radiographic Findings that Support HPP Diagnosis

- Infantile rickets
- Alveolar bone loss
- Focal bony defects of the metaphyses
- Metatarsal stress fractures
- Osteomalacia with lateral pseudofractures
- Osteopenia, osteoporosis, or low bone mineral content for age (as detected by dual-energy x-ray absorptiometry [DEXA])

I attest that this information is accurate and true, and that documentation supporting this	
information is available for review if requested by CVS Caremark or the benefit plan sponso	r.

X	
Prescriber or Authorized Signature	Date (mm/dd/yy

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Strensiq SGM - 6/2021.